

# Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11 $\beta$ -hydroxylase deficiency

Ahmed Khattab<sup>a,b,1,2</sup>, Shozeb Haider<sup>c,1</sup>, Ameet Kumar<sup>a,b,1</sup>, Samarth Dhawan<sup>a,b</sup>, Dauood Alam<sup>a,b</sup>, Raquel Romero<sup>c</sup>, James Burns<sup>c</sup>, Di Li<sup>c</sup>, Jessica Estatico<sup>a,b</sup>, Simran Rahi<sup>a,b</sup>, Saleel Fatima<sup>a,b</sup>, Ali Alzahrani<sup>d</sup>, Mona Hafez<sup>e</sup>, Noha Musa<sup>e</sup>, Maryam Razzghy Azar<sup>f</sup>, Najoua Khaloul<sup>g</sup>, Moez Gribaa<sup>g</sup>, Ali Saad<sup>g</sup>, Ilhem Ben Charfeddine<sup>g</sup>, Berenice Bilharinho de Mendonça<sup>h</sup>, Alicia Belgorosky<sup>i</sup>, Katja Dumic<sup>j</sup>, Miroslav Dumic<sup>j</sup>, Javier Aisenberg<sup>k</sup>, Nurgun Kandemir<sup>l</sup>, Ayfer Alikasifoglu<sup>l</sup>, Alev Ozon<sup>l</sup>, Nazli Gonc<sup>l</sup>, Tina Cheng<sup>a,b</sup>, Ursula Kuhnle-Krahl<sup>m</sup>, Marco Cappa<sup>n</sup>, Paul-Martin Holterhus<sup>o</sup>, Munier A. Nour<sup>p</sup>, Daniele Pacaud<sup>q</sup>, Assaf Holtzman<sup>a,b</sup>, Sun Li<sup>a,b</sup>, Mone Zaidi<sup>a,b,2</sup>, Tony Yuen<sup>a,b,2</sup>, and Maria I. New<sup>a,b,2,3</sup>

<sup>a</sup>Division of Adrenal Steroid Disorders, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029; <sup>b</sup>Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029; <sup>c</sup>School of Pharmacy, University College London, London WC1N 4AX, United Kingdom; <sup>d</sup>King Faisal Specialist Hospital and Research Centre, Riyadh 12713, Saudi Arabia; <sup>e</sup>Diabetes, Endocrine, and Metabolism Pediatrics Unit, Department of Pediatrics, Cairo University, 11617 Cairo, Egypt; <sup>f</sup>Ali Asghar Children's Hospital, Iran University of Medical Sciences, 10000 Tehran, Iran; <sup>g</sup>Laboratory of Human Cytogenetic Molecular Genetics and Biology of Reproduction, Farhat Hached University Hospital, Sousse, Tunisia; <sup>h</sup>Developmental Endocrinology Unit, Hormone and Molecular Genetics Laboratory, University of São Paulo, Sao Paulo 05508, Brazil; <sup>i</sup>Garrahan Pediatric Hospital, 1881 Buenos Aires, Argentina; <sup>j</sup>University Hospital Centre Zagreb, 10000 Zagreb, Croatia; <sup>k</sup>Pediatric Endocrinology and Diabetes Medicine, Hackensack University Medical Center, Hackensack, NJ 07601; <sup>l</sup>Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey; <sup>m</sup>Childrens Hospital, University of Munich, 80539 Munich, Germany; <sup>n</sup>Bambino Gesù Hospital, 00146 Roma, Italy; <sup>o</sup>Department of Pediatrics, University Hospital of Schleswig-Holstein, 24105 Kiel, Germany; <sup>p</sup>Department of Pediatrics, University of Saskatchewan College of Medicine, Saskatoon, SK, Canada S7N 0W8; and <sup>q</sup>Department of Pediatrics, University of Calgary, Calgary, AB, Canada T3B 6A8

Contributed by Maria I. New, January 3, 2017 (sent for review October 26, 2016; reviewed by Vidya Darbari, Joe Leigh Simpson, and Rajesh V. Thakker)

**Congenital adrenal hyperplasia (CAH), resulting from mutations in *CYP11B1*, a gene encoding 11 $\beta$ -hydroxylase, represents a rare autosomal recessive Mendelian disorder of aberrant sex steroid production. Unlike CAH caused by 21-hydroxylase deficiency, the disease is far more common in the Middle East and North Africa, where consanguinity is common often resulting in identical mutations. Clinically, affected female newborns are profoundly virilized (Prader score of 4/5), and both genders display significantly advanced bone ages and are oftentimes hypertensive. We find that 11-deoxycortisol, not frequently measured, is the most robust biochemical marker for diagnosing 11 $\beta$ -hydroxylase deficiency. Finally, computational modeling of 25 missense mutations of *CYP11B1* revealed that specific modifications in the heme-binding (R374W and R448C) or substrate-binding (W116C) site of 11 $\beta$ -hydroxylase, or alterations in its stability (L299P and G267S), may predict severe disease. Thus, we report clinical, genetic, hormonal, and structural effects of *CYP11B1* gene mutations in the largest international cohort of 108 patients with steroid 11 $\beta$ -hydroxylase deficiency CAH.**

steroid hormones | missense mutations | classic CAH | ambiguous genitalia

Congenital adrenal hyperplasia (CAH) is a Mendelian disorder transmitted as an autosomal recessive trait. The most prevalent form of CAH arises from steroid 21-hydroxylase enzyme deficiency, accounting for ~90–95% of all cases (1, 2). In contrast, CAH caused by steroid 11 $\beta$ -hydroxylase deficiency is considerably rare, with a prevalence of 5–8% (3), from which we estimate an overall frequency of 1 in 100,000 live births.

Two homologous enzymes, 11 $\beta$ -hydroxylase and aldosterone synthase, are encoded by the *CYP11B1* and *CYP11B2* genes, respectively. The two genes are 40-kb apart, each comprising nine exons and mapped to chromosome 8q21-22 (3, 4) (Fig. 1A). In contrast to *CYP21A2* and its *CYP21A1P* pseudogene, *CYP11B1* and *CYP11B2* are both active and do not have a pseudogene. The two encoded homologs, however, have distinct functions in cortisol and aldosterone synthesis, respectively (3). In the zona fasciculata, 11 $\beta$ -hydroxylase converts 11-deoxycortisol and 11-deoxycorticosterone to cortisol and corticosterone, respectively, and is regulated by adrenocorticotrophic hormone secreted by the pituitary. In contrast, in the zona glomerulosa aldosterone synthase converts corticosterone to aldosterone with the intermediate production of 18-hydroxycorticosterone. These latter conversions are controlled mainly by the renin angiotensin II system and serum potassium concentration (3).

Deficiency of 11 $\beta$ -hydroxylase prevents the conversion of 11-deoxycortisol to cortisol and 11-deoxycorticosterone to corticosterone. This results in high levels of 11-deoxycortisol and 11-deoxycorticosterone, respectively, which are shunted into the androgen synthesis pathway, resulting in high levels of the androgenic steroid, androstenedione. Female newborns are thus profoundly virilized and exhibit significant masculinization of the external genitalia (5). Precocious puberty, rapid somatic growth, and rapid skeletal maturation because of hyperandrogenemia occur in both genders. Accumulation of the potent mineralocorticoid 11-deoxycorticosterone also leads to hypertension, which is not seen with 21-hydroxylase deficiency.

We recently published evidence for genotype–phenotype concordance in 1,507 families with 21-hydroxylase deficiency; however, 7% of the patients demonstrated nonconcordance (6). In a separate study, we used computational modeling to define in silico the structural

## Significance

**Congenital adrenal hyperplasia resulting from mutations in the *CYP11B1* gene, which encodes a steroidogenic enzyme 11 $\beta$ -hydroxylase, is a rare inherited disorder associated with hyperandrogenemia, short stature, hypertension, and virilization of female newborns. We present a comprehensive clinical, genetic, and hormonal characterization for 68 of 108 patients with a genotype from an International Consortium on Rare Steroid Disorders. We also use computational modeling to define the effect of each of the missense mutations on the structure of 11 $\beta$ -hydroxylase, information that can be used to predict clinical severity prenatally in high-risk mothers.**

Author contributions: M.Z., T.Y., and M.I.N. designed research; S.H., A. Kumar, S.D., D.A., R.R., J.B., D.L., J.E., A. Alzahrani, and N.M. performed research; A. Khattab, S.H., A. Kumar, R.R., J.B., D.L., J.E., S.R., S.F., A. Alzahrani, M.H., M.R.A., N. Khaloul, M.G., A.S., I.B.C., B.B.d.M., A.B., K.D., M.D., J.A., N. Kandemir, A. Alikasifoglu, A.O., N.G., T.C., U.K.-K., M.C., P.-M.H., M.A.N., D.P., A.H., S.L., M.Z., T.Y., and M.I.N. analyzed data; and A. Khattab, S.H., M.Z., T.Y., and M.I.N. wrote the paper.

Reviewers: V.D., Queen Mary University of London; J.L.S., March of Dimes Foundation; and R.V.T., University of Oxford.


The authors declare no conflict of interest.

<sup>1</sup>A. Khattab, S.H., and A. Kumar contributed equally to this work.

<sup>2</sup>A. Khattab, M.Z., T.Y., and M.I.N. contributed equally to this work.

<sup>3</sup>To whom correspondence should be addressed. Email: maria.new@mssm.edu.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1621082114/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1621082114/-DCSupplemental).



**Fig. 1.** Clinical profile for patients with CAH resulting from 11 $\beta$ -hydroxylase deficiency from 13 nations comprising the International Consortium for Rare Steroid Disorders. (A) Structure of the human *CYP11B1* gene that contains nine exons, showing mutations harbored by 108 patients in this international cohort. Previously unreported mutations are shown in italics. (B) Worldwide distribution of our cases of 11 $\beta$ -hydroxylase deficiency. The denominator indicates the number of patients originating from that country with 11 $\beta$ -hydroxylase deficiency. The numerator indicates the number of patients with 11 $\beta$ -hydroxylase deficiency who have been genotyped. All patients who originated from Middle East and European countries have been placed in their respective countries. It is evident from this map that the majority of patients with 11 $\beta$ -hydroxylase deficiency originate in the Middle East and North Africa. (C) Prader scores of patients with different genotypes (noted), both as homozygotes and compound heterozygotes. One patient (green) has been treated prenatally with dexamethasone. (D) Bone age versus chronological age in male (blue) and female (red) patients. The black line represents a slope of 1 (bone age = chronological age). Of note is that almost all patients show evidence of advanced bone age. (E) Mean arterial pressure (1/3 systolic pressure + 2/3 diastolic pressure) shown for both males and female patients of various ages. The two lines indicate the age-appropriate upper and lower limits of the normal range. (F) Measurements of 11-deoxycortisol (red) and 11-deoxycorticosterone (green) in our patient cohort. Shown also are normal reference ranges for both hormones (horizontal lines; Esoterix).

changes that each mutation in the *CYP21A2* gene induces in the 21-hydroxylase enzyme, and by correlating these changes with phenotype,

defined structural derangements underpinning the clinical variants of CAH, namely salt-wasting, simple virilizing, and nonclassic CAH (7).

Studies reporting the clinical and hormonal phenotype of 11 $\beta$ -hydroxylase deficiency have been restricted because of small patient numbers, consistent with the rarity of this disease. As the International Consortium of Rare Steroid Disorders, we now provide extensive data on the demographics, genotype, phenotype, and hormonal profile of CAH patients with 11 $\beta$ -hydroxylase deficiency. Although we had 220 patients reported to us with clinical data, only 108 patients had been genotyped and are reported herein.

Our dataset confirms ethnic and geographical predominance of 11 $\beta$ -hydroxylase deficiency in Middle East and North African nations, in contrast to 21-hydroxylase deficiency that affects mainly Eastern Europeans of Jewish descent, with 1 in 27 patients having mild, nonclassic CAH (8). Our data also show that mostly all CAH patients with 11 $\beta$ -hydroxylase deficiency display rapid skeletal maturation, with their bone age exceeding chronological age; show higher Prader scores than newborns with 21-hydroxylase deficiency; and commonly suffer from hypertension. Computational modeling indicates that, as with 21-hydroxylase deficiency, mutation-induced changes in the heme- or substrate binding regions of 11 $\beta$ -hydroxylase and mutations affecting enzyme stability cause severe CAH.

## Results

CAH resulting from 11 $\beta$ -hydroxylase deficiency is a rare disorder with reported prevalence of 1 in 100,000 live births (2, 3). In our international cohort, the disease was confined mainly to Middle East and North African nations, where consanguinity is common. Of note, 58% of patients were from consanguineous marriages (Table 1) (9–13). The median age of diagnosis was 1.08 y (range: 0–17 y), with 80% of females being diagnosed because of ambiguous genitalia at birth. In contrast, 84% of males presented later with precocious puberty, and the remaining cases were diagnosed upon screening triggered by hypertension, hyperpigmentation, or family history. Of the 14 46, XX patients who were assigned as males at birth, 10 were subsequently reassigned to the female sex.

Fig. 1A shows that, in our cohort of 108 patients, there were 31 missense, 5 nonsense, 1 insertion, and 9 frameshift mutations of the *CYP11B1* gene, as well as 4 splice-site mutations. Country distribution of these patients is shown in Fig. 1B. Mutations in 56 patients have been published in smaller collaborative studies (14–21). In our current cohort, 30 patients with the G379V/G379V mutation were Arab Berbers from Tunisia, 4 with G446V/G446V were from Egypt, and 4 with Q19Afs\*21/Q19Afs\*21 were from Saudi Arabia. Only five patients with the genotype A331V/A331V were Sephardic Jews living in the United States (Table 1).

Fig. 1 and Table S1 provide detailed clinical and hormonal evaluations. Of the 108 patients studied, 55 were females, but Prader scores were reported for 39 patients. Of these, eight females had a Prader score of 5 (21%) (Fig. 1C). Notably, their external genitalia displayed significant masculinization, with the urethra opening at the tip of the phallus. Of the 39 females, 18 had Prader scores of 4 (46%). In a different subset of 70

patients, all had advanced bone age, with males significantly exceeding females (bone age/chronological age; males:  $2 \pm 0.82$ ,  $n = 40$ ; females:  $1.43 \pm 0.44$ ,  $n = 30$ ) ( $P = 0.0008$ ) (Fig. 1D).

Measurement of baseline mean arterial pressures (MAP) in another subset of 70 patients showed that 38 were hypertensive, with MAPs exceeding the upper limit of normal for age (Fig. 1E). There was no significant difference in MAP between males ( $n = 34$ ) and females ( $n = 36$ ). There was a trend for higher MAPs in older children, but sporadic high MAPs were noted even in younger patients. Adrenal steroid hormones were measured by mass spectrometry in the local laboratory of the country. Serum 11-deoxycortisol and 11-deoxycorticosterone levels were all elevated, consistent with 11 $\beta$ -hydroxylase deficiency (Fig. 1F and Table S1).

To understand whether the clinical phenotype of 11 $\beta$ -hydroxylase deficiency could be predicted by examining changes in enzyme structure induced by a given *CYP11B1* mutation, we performed in silico analytics using the human *CYP11B1* model constructed using the homologous *CYP11B2* crystal structure as a template (PDB ID code 4DVQ), which exhibited 93% sequence similarity over 478 residues. We have previously shown that the clinical phenotype of patients with 21-hydroxylase deficiency correlates with the extent of functional loss induced by a given mutation (7). For example, missense mutations within 5 Å of the heme- or substrate-binding region or those affecting stability of 21-hydroxylase resulted in severe salt-wasting CAH, whereas mutations disrupting conserved hydrophobic patches or transmembrane interactions caused the less severe, simple virilizing disease (7). Our model for *CYP11B1* exhibited structural features of a classic steroid-synthesizing cytochrome, with a triangular prism structure containing 16  $\alpha$ -helices and 9  $\beta$ -sheets (Fig. 2A and B and Fig. S1).


We analyzed each mutation in relation to its severity in terms of causing advanced bone age, poor Prader scores, and elevated MAPs. Patients with mutations of R374 showed high Prader scores of 4, advanced bone age, and severe hypertension. Structural analysis showed that R374, a conserved residue across the cytochrome family, creates an ion-pair interaction with E371 at the end of the K-helix. The helix continues into a loop that forms a part of the heme-binding site. The ion pair R374-E371 is responsible for maintaining the heme-binding site, and its mutation is therefore predicted to be disruptive (Fig. 2C).

However, unlike the *CYP21A2* gene, not all mutations within the heme-binding site of *CYP11B1* yield a severe phenotype. For example, residue R448, located on a loop between the meander region and L-helix, forms a part of the heme-binding site. It creates hydrogen bonds with the propionate tail of heme, the backbone atoms of L132, and the side chain of N133 (Fig. 2D–F). However, whereas its mutation is expected to result in a loss of these hydrogen bonds, the clinical phenotype depends on whether the mutant residue is Cys, His, or Pro. The R448C mutation was associated with profoundly advanced bone age and severe hypertension, and the Prader scores of the R448C and R448H were 4/5. In contrast, mutation to Pro, which has a rigid backbone structure, preserves the local structure around the propionate tails. Thus, R448P was very mild, with a Prader score of 1.

Certain mutations were also found to adversely affect enzyme stability, and were therefore not well tolerated. L299 is a conserved residue located on the turn between the H- and J-helices, and its mutation to a more rigid Pro side chain was found to decrease flexibility of the turn, thus impairing enzyme stability (Fig. 2G). Patients homozygous for this mutation showed Prader scores between 4 and 5, advanced bone ages, and high MAPs. Another mutation, G267S, likewise produced severe virilization (Prader score 5) and marked increases in bone age (MAPs not available). The residue G267S is located on the G-helix, and its mutation to Ser resulted in lost flexibility, as side chains of the bulkier Ser did not fit between the G- and J-helices. This caused steric clashes with residues on J-helix, significantly impairing enzyme stability (Fig. 2H).

**Table 1. Number of patients with congenital adrenal hyperplasia because of steroid 11 $\beta$  hydroxylase deficiency in Tunisia, Iran, Egypt, Turkey, and Saudi Arabia**

Country	Patients	Population, million	Consanguinity, % (ref.)
Tunisia	60	11	20.1–39.3 (9)
Iran	44	77	38.6 (10)
Egypt	26	82	28.96 (11)
Turkey	28	75	33.9 (12)
Saudi Arabia	11	29	52 (13)



**Fig. 2.** Modeling severe disruptive mutations affecting heme- or substrate-binding or CYP11B1 stability. Human CYP11B1 model constructed using the homologous CYP11B2 crystal structure as a template (PDB ID code 4DVQ), shown as side view showing the inner mitochondrial membrane bilayer and the bound heme (green) and deoxycorticosterone (DOC, pink) (A). Also shown are the positions of the  $\alpha$ -helices,  $\beta$ -sheets, and the mutations analyzed in this study (B). R374 creates an ion-pair interaction with E371 at the end of the K-helix, which continues into a loop that forms a part of the heme-binding site (C). Mutation of this ion pair R374-E371 is disruptive. Mutations affecting the heme-binding site may not all be as disruptive, depending on the mutated residue. For example, residue R448, located on a loop between the meander region and L-helix, forms a part of the heme-binding site, and creates hydrogen bonds with the propionate tail of heme, the backbone atoms of L132, and the side chain of N133. Its mutation to Cys (D) or His (E) causes severe disruption, whereas substitution to Pro does not (F). Pro enhances rigidity of the loop, whereas the loop in the Cys/His mutants moves away from the vicinity of heme. L299 is located on the turn between the H- and J-helices, and its mutation to a more rigid Pro side chain decreases flexibility of the turn, thus impairing enzyme stability (G). G267S is located on the G-helix, and its mutation to Ser results in lost flexibility, as side chains of the bulkier Ser does not fit between G- and J-helices, causing steric clashes with residues on J-helix, significantly impairing enzyme stability (H). W116 is located on B'-helix, with its aromatic indole side chain surrounded by the aromatic side chains of F130, F231, W260, F287, and hydrophobic side chain of L113; these residues form the roof of the binding site of the aromatic substrate. A mutation to Cys disrupts the substrate-binding site (I). (J) The change ( $\Delta\Delta G$  kcal/mol) in protein stability upon mutation of each residue. A positive energy value indicates that the mutation is likely to be disruptive. The disks represent the pairwise atomic van der Waals radii overlap. Green disks represent almost in contact or slightly overlapping and red disks represent significant overlap.

In addition to mutations affecting the heme-binding region or enzyme stability, we also identified a mutation, W116C, which affects substrate-binding. W116 is located on B'-helix, with its aromatic indole side chain surrounded by the aromatic side chains of F130, F231, W260, F487, and hydrophobic side chain of L113. These residues together form the roof of the binding site of the aromatic substrate, and a mutation to Cys was found to

disrupt the substrate-binding site (Fig. 2I). CAH patients with this mutation had Prader scores of 4 and were severely hypertensive, but one patient had an unexplained normal bone age.

We also identified mutations that were not as severe, wherein  $11\beta$ -hydroxylase structure was not as adversely affected *in silico*. For example, we found that the end of the J-helix contained a conserved residue, A331, which when mutated to Val, clashed

sterically with residues on the  $\beta 5$ -sheet (Fig. 3*A*). Patients with A331V displayed Prader scores between 2 and 4, modest increases in bone age, and normal MAPs. Another relatively “mild” mutation was G206V, in which patients had Prader scores of 3 but with normal MAPs. The highly conserved and flexible residue G206 is located at the end of the E-helix. When mutated to Val, the side chains clashed sterically with F205 and T287, but only mildly impairing enzyme stability (Fig. 3*B*).

We also investigated mutations for which severity of the three clinical parameters, namely Prader scores, bone age, and MAP, did not correlate with the structural disruption caused by mutations. Mutation of T318, a highly conserved residue located on the J-helix, to Met resulted in a Prader score of 4, but with normal bone age and mild hypertension. Computationally, the hydrophobic side chains clashed sterically with heme to obstruct the ligand-binding site, but the enzyme appeared by and large intact and stable (Fig. 3*C*). In contrast, G379, located on a loop between the K-helix and  $\beta 4$ -sheet, is positioned adjacent to the substrate-binding site. The isopropyl side chain of the mutated residue Val was found to obstruct and thus misalign the substrate, again without severely affecting the enzyme (Fig. 3*D*). Clinically, this mutation was associated with advanced bone age but relatively mild hypertension.


Two Prader 4 mutations, namely P94L and T318R, for which we have limited clinical information in our cohort, also deserve mention. The P94 residue is located on the B-helix. When mutated to Leu, the hydrophobic side chain clashes sterically with the loop between the  $\alpha 17$ - and  $\alpha 18$ -helices. The rigid amino acid side chain also maintains the structural conformation between the B'-helix and  $\beta 2$ -sheet (Fig. 3*E*). In case of the T318R mutation, the charged guanidinium side chains of Lys clashed sterically with heme to obstruct the ligand-binding site (Fig. 3*F*).

Fig. 4 is a compendium of structural changes induced by mutations that constitute compound heterozygote genotypes. The overall phenotypic severity in compound heterozygotes will depend on the relative contribution of each mutated protein. We also provide details of structural changes induced by mutations published by others (Figs. S2 and S3). Finally, two nonsense mutations, wherein the protein produced should be truncated, namely homozygous R141X and W260X mutations, were found to be associated with expectedly high Prader scores of 4/5. Similarly, patients with truncated frameshift mutations, namely F406Pfs\*19 and Q19Afs\*21, also had high Prader scores ranging from 3 to 5. However, the noted MAPs for all four genotypes were surprisingly normal.

## Discussion


This study provides a detailed description of the largest international, heterogeneous cohort of 108 CAH patients with 11 $\beta$ -hydroxylase deficiency from 11 countries (Fig. 1*B*). In contrast to CAH resulting from 21-hydroxylase deficiency, the prevalence of which is particularly high in Eastern European Jews, 11 $\beta$ -hydroxylase deficiency is common in the Middle East and North Africa. We report a spectrum of clinical severities across mutation types. Because performing *in vitro* expression studies for this large number of mutations is an enormous effort, we instead attempted, using computational modeling, to correlate the induced *in silico* changes in 11 $\beta$ -hydroxylase structure with clinical phenotype, which is predictive, not confirmatory.

We found that 41 compound heterozygotes or homozygotes for select missense or nonsense mutations—namely P49L, R141Q, W260X, G267S, L299P, T318M, T318R, A331V, Q356X, A368D, R374Q, V441G, G444D, G446V, and R448H—present with moderate to severe classic CAH because of 11 $\beta$ -hydroxylase, confirming prior results (3, 14–17, 22–24). These patients were mainly from Croatia, Tunisia, Africa, Turkey, and Saudi Arabia. Prader scores for females were consistently 4 or 5, but serum 11-deoxycorticosterone, 11-deoxycortisol, and androstenedione levels, albeit elevated, were



**Fig. 3.** Modeling of CYP11B1 mutations that do not yield a severe phenotype. A331 is a conserved residue at the end of the J-helix. When mutated to Val, it clashes sterically with residues on  $\beta 5$  sheet (A). G206 is located at the end of the E-helix. When mutated to Val, the side chains clash sterically with F205 and T287, but only mildly impairing enzyme stability (B). Both mutations yielded mild phenotypes. With certain mutations the three clinical parameters, Prader scores, bone age, and MAP, did not match. T318 is a highly conserved residue located on the J-helix. Hydrophobic side chains of the mutated Met residue sterically clash with heme to obstruct the ligand-binding site (C). G379, located on a loop between K-helix and  $\beta 4$ -sheet, is positioned adjacent to the substrate-binding site. The isopropyl side chain of the mutated residue Val obstructs and thus misaligns the substrate (D). P94, located on the B-helix, when mutated to Leu, causes the hydrophobic side chain to clash sterically with the loop between the  $\alpha 17$ - and  $\alpha 18$ -helices. The rigid amino acid side chain also maintains the structural conformation between B'-helix and  $\beta 2$ -sheet (E). With the T318R mutation, the charged guanidinium side chains of Lys clash sterically with heme to obstruct the ligand-binding site (F). (G) The change ( $\Delta\Delta G$  kcal/mol) in protein stability upon mutation of each residue. The disks represent the pairwise atomic van der Waals radii overlap. Green disks represent almost in contact or slightly overlapping, and red disks represent significant overlap.

highly variable. Bone age was advanced in most cases, but hypertension was diagnosed only in ~59% of patients.



**Fig. 4.** Modeling of CYP11B1 mutations harbored by compound heterozygotes. The following mutations were modeled: R141Q (A); T319M (B); G444D (C); R43Q (D); A386V (E); L407F (F); V441G (G); N133H (H); R138C (I); E198G (J); S288R (K); A368D (L); R453Q (M); and R453W (N). (O) The change ( $\Delta\Delta G$  kcal/mol) in protein stability upon mutation of each residue. The disks represent the pairwise atomic van der Waals radii overlap. Green disks represent almost in contact or slightly overlapping, and red disks represent significant overlap.

Even with the concordance noted above, we failed to establish a previously documented phenotype in the N133H/T319M mutation (3, 25). Based on in vitro data, advanced bone age, and a Tanner score of 2, a N133H/T319M female was previously assigned a diagnosis of nonclassic CAH because of 11 $\beta$ -hydroxylase.

We found instead that three patients of Egyptian origin, two males and one female with the identical genotype N133H/T319M, present with classic disease, which we have documented both clinically and hormonally. Each patient had grossly elevated serum 11-deoxycortisol and androstenedione

levels and advanced bone age. The one female had Prader score 4, and one patient had hypertension.

Comparison of our International Consortium on Rare Steroid Disorders with our mainly United States-based, 1,507-patient, 21-hydroxylase deficiency cohort (6) reveals fundamental differences in clinical phenotype. First, 11 $\beta$ -hydroxylase deficiency is far less common, and is localized to the Middle East and North Africa. Second, females with 11 $\beta$ -hydroxylase deficiency are more virilized than those with 21-hydroxylase deficiency. A Prader score of 5, indicating complete masculinization of the external genitalia, including a urethral opening at the tip of the phallus, is more frequent in 11 $\beta$ -hydroxylase deficiency than in 21-hydroxylase deficiency. The extent of masculinization, however, correlates poorly with the accompanying gross hyperandrogenemia. Third, and related to virilization, it is more common that a 46, XX 11 $\beta$ -hydroxylase-deficient newborn female is assigned a male gender. In our cohort, most such 46, XX females, misassigned to the male gender at birth, were reared as males, although some were subsequently reassigned to the female gender. Fourth, 21-hydroxylase deficiency is not associated with hypertension, whereas 59% of 11 $\beta$ -hydroxylase-deficient patients in whom blood pressures were measured were hypertensive (26, 27). Correlations between 11-deoxycorticosterone and hypertension were nonetheless poor. Fifth, whereas 17-hydroxyprogesterone is a gold standard for the biochemical diagnosis of 21-hydroxylase deficiency (1), we find that the most robust serum marker for 11 $\beta$ -hydroxylase deficiency is the accumulated substrate 11-deoxycortisol. However, as this steroid is not routinely measured, we predict that 11 $\beta$ -hydroxylase deficiency is underdiagnosed. Finally, one patient with full blown CAH was interestingly a heterozygote with a common mutation G379V. Possibilities for disease in this patient include a genotyping error, a cryptic intronic mutation, or a dominant-negative effect.

To study genotype–structure–phenotype concordance, we examined whether mutations in the *CYP11B1* gene could induce specific changes in 11 $\beta$ -hydroxylase that would correlate with CAH severity. We have recently used computational modeling to establish structural aberrations in 21-hydroxylase induced by mutations that explained distinct phenotypes, namely salt-wasting, simple virilizing, and nonclassic CAH (7). Most notably, missense mutations that affected residues within 5 Å of the heme- or substrate-binding site or altered protein stability led to salt-wasting CAH, whereas mutations affecting conserved hydrophobic patches or altering the transmembrane region caused simple virilizing disease. Mild nonclassic CAH resulted from interference in oxidoreductase interactions, salt-bridge and hydrogen-bonding networks, and nonconserved hydrophobic clusters.

Here, a similar evaluation using a *CYP11B1* model, derived from the crystal structure of *CYP11B2*, revealed three groups of mutations that caused severe disease. Mutations that altered the heme-binding site, such as R374W and R448H/C, resulted in high Prader scores (4/5), severe hypertension, and profoundly advanced bone age. Similar clinical manifestations arose from mutations that affected enzyme stability, such as L299P and G267S, or interfered with

substrate-binding, notably W116C. With that said, there were mutations where the three key clinical parameters, Prader scores, bone age, and MAP, did not correlate with structural disruption caused by mutations. For example, the T318M mutation was associated with a Prader score of 4, but with normal bone age and mild hypertension. Similarly, G379V appeared to be associated with advanced bone age but relatively mild hypertension.

In summary, we report that CAH caused by 11 $\beta$ -hydroxylase deficiency is far less frequent than that arising from 21-hydroxylase deficiency, thus requiring an international collaborative cohort to obtain sufficient number of patients for analysis. The disease was most prevalent in Tunisia (60 patients in a population of 11 million), where consanguinity is common (Table 1). However, as 11-deoxycortisol is rarely measured, the overall prevalence could in fact be an underestimate. Our cohort of 108 patients nonetheless revealed greater morbidity than 21-hydroxylase deficiency. There was profound masculinization, significant early growth arrest, and overt hypertension. Finally, although we were able to correlate structural changes of certain highly disruptive mutations of 11 $\beta$ -hydroxylase with the severity of CAH, unlike 21-hydroxylase deficiency, this strategy could not be applied universally.

## Methods

The studies were approved by the Icahn School of Medicine's Institutional Review Board (IRB) (PI: M.I.N), and by local hospital IRBs, as confirmed by on-site investigators comprising the International Consortium of Rare Steroid Disorders. Informed consent was obtained. To those who agreed to be part of the Consortium, we sent data entry forms, asking for information on demographics, consanguinity, clinical presentation, adrenal steroid hormone levels, and *CYP11B1* mutations, at the time of diagnosis. We also requested information on bone age, Prader scores, and baseline blood pressure measurements. We received entry forms from investigators from 13 nations with data on 108 patients with *CYP11B1* mutations confirming 11 $\beta$ -hydroxylase deficiency (Fig. 1B and Table S1). Of these, 66 patients have complete datasets. Leading endocrinologists in Australia, Canada, Chile, Dominican Republic, Finland, France, Greece, Italy, Japan, Qatar, Spain, Sweden, Switzerland, United Arab Emirates, and United Kingdom reported no CAH patients with 11 $\beta$ -hydroxylase deficiency. Similarly and to our surprise, seven leading endocrinologists in California, Connecticut, Michigan, New York, Pennsylvania, and Texas did not have a single patient.

Each mutation was analyzed for its ability to disrupt the *CYP11B1* enzyme using molecular dynamics modeling (*SI Methods*). The change ( $\Delta\Delta G$  kcal/mol) in protein stability upon mutation of a single residue was calculated using the Molsoft ICM-Pro software ([www.molsoft.com](http://www.molsoft.com)). The free energy of the unfolded and misfolded states is approximated by a sum of the residue-specific energies that were derived empirically using experimental data. Mutation of a given residue was followed by Monte Carlo simulations with flexible side chains for the mutated residue and its neighboring residues. The rest of the protein structure was considered rigid. A positive energy value thus indicates that the mutation is likely to be destabilizing (28).

**ACKNOWLEDGMENTS.** The study was supported by the Maria I. New Children Hormone Foundation; and NIH Grants DK80459 (to M.Z. and S.L.), AG40132 (to M.Z.), AR06592 (to M.Z.), and AR06066 (to M.Z.). S.H. received funding from a University College London Excellence fellowship.

1. New MI, Lekarev O, Mancenido D, Parsa A, Yuen T (2014) Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. *Genetic Steroid Disorders*, eds New MI, et al. (Academic, San Diego), pp 29–51.
2. Mancenido D, New MI (2014) The history of prenatal diagnosis of congenital adrenal hyperplasia. *Genetic Steroid Disorders*, eds New MI, et al. (Academic, San Diego), pp 53–62.
3. White PC (2014) Steroid 11 $\beta$ -hydroxylase deficiency and related disorders. *Genetic Steroid Disorders*, eds New MI, et al. (Academic, San Diego), pp 71–85.
4. Chua SC, et al. (1987) Cloning of cDNA encoding steroid 11 beta-hydroxylase (P450c11). *Proc Natl Acad Sci USA* 84(20):7193–7197.
5. Zachmann M, Tassinari D, Prader A (1983) Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. *J Clin Endocrinol Metab* 56(2):222–229.
6. New MI, et al. (2013) Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. *Proc Natl Acad Sci USA* 110(7):2611–2616.
7. Haider S, et al. (2013) Structure-phenotype correlations of human *CYP21A2* mutations in congenital adrenal hyperplasia. *Proc Natl Acad Sci USA* 110(7):2605–2610.
8. Speiser PW, et al. (1985) High frequency of nonclassical steroid 21-hydroxylase deficiency. *Am J Hum Genet* 37(4):650–667.
9. Tadmouri GO, et al. (2009) Consanguinity and reproductive health among Arabs. *Reprod Health* 6:17.
10. Saadat M, Ansari-Lari M, Farhud DD (2004) Consanguineous marriage in Iran. *Ann Hum Biol* 31(2):263–269.
11. Hafez M, et al. (1983) Consanguineous matings in the Egyptian population. *J Med Genet* 20(1):58–60.
12. Alper OM, et al. (2004) Consanguineous marriages in the province of Antalya, Turkey. *Ann Genet* 47(2):129–138.
13. al-Abdulkareem AA, Ballal SG (1998) Consanguineous marriage in an urban area of Saudi Arabia: Rates and adverse health effects on the offspring. *J Community Health* 23(1):75–83.
14. Motaghed R, et al. (2005) Update on the prenatal diagnosis and treatment of congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency. *J Pediatr Endocrinol Metab* 18(2):133–142.
15. Dumic K, et al. (2014) Two novel *CYP11B1* gene mutations in patients from two croatian families with 11  $\beta$ -hydroxylase deficiency. *Int J Endocrinol* 2014:185974.

16. Kandemir N, et al. (2017) Novel and prevalent CYP11B1 gene mutations in Turkish patients with 11-beta hydroxylase deficiency. *J Steroid Biochem Mol Biol* 165(Pt A): 57–63.
17. Krone N, et al. (2006) Analyzing the functional and structural consequences of two point mutations (P94L and A368D) in the CYP11B1 gene causing congenital adrenal hyperplasia resulting from 11-hydroxylase deficiency. *J Clin Endocrinol Metab* 91(7): 2682–2688.
18. Soardi FC, et al. (2009) Novel mutations in CYP11B1 gene leading to 11 beta-hydroxylase deficiency in Brazilian patients. *J Clin Endocrinol Metab* 94(9): 3481–3485.
19. Dumic K, et al. (2010) Steroid 11-beta hydroxylase deficiency caused by compound heterozygosity for a novel mutation in intron 7 (IVS 7 DS+4A to G) in one CYP11B1 allele and R448H in exon 8 in the other. *Eur J Pediatr* 169(7):891–894.
20. Bin-Abbas B, et al. (2014) Divergent gender identity in three siblings with 46XX karyotype and severely virilizing congenital adrenal hyperplasia caused by a novel CYP11B1 mutation. *Endocr Pract* 20(10):e191–e197.
21. Ben Charfeddine I, et al. (2012) Two novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11 $\beta$  hydroxylase deficiency in a Tunisian family. *Gen Comp Endocrinol* 175(3):514–518.
22. Alqahtani MA, et al. (2015) A novel mutation in the CYP11B1 gene causes steroid 11 $\beta$ -hydroxylase deficient congenital adrenal hyperplasia with reversible cardiomyopathy. *Int J Endocrinol* 2015:595164.
23. Curnow KM, et al. (1993) Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. *Proc Natl Acad Sci USA* 90(10):4552–4556.
24. Krone N, et al. (2005) Congenital adrenal hyperplasia due to 11-hydroxylase deficiency: Functional characterization of two novel point mutations and a three-base pair deletion in the CYP11B1 gene. *J Clin Endocrinol Metab* 90(6): 3724–3730.
25. Joehrer K, et al. (1997) CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. *Hum Mol Genet* 6(11):1829–1834.
26. Rösler A, Leiber E, Cohen T (1992) High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. *Am J Med Genet* 42(6):827–834.
27. Kandemir N, Yordam N (1997) Congenital adrenal hyperplasia in Turkey: A review of 273 patients. *Acta Paediatr* 86(1):22–25.
28. Rashin AA, Rashin BH, Rashin A, Abagyan R (1997) Evaluating the energetics of empty cavities and internal mutations in proteins. *Protein Sci* 6(10):2143–2158.
29. Sievers F, Higgins DG (2014) Clustal omega. *Curr Protoc Bioinformatics* 48: 3.13,1–3.13.16.
30. Sievers F, Higgins DG (2014) Clustal omega, accurate alignment of very large numbers of sequences. *Methods Mol Biol* 1079:105–116.
31. Webb B, Sali A (2016) Comparative protein structure modeling using MODELLER. *Curr Protoc Bioinformatics* 54:5.6.1–5.6.37.
32. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM (1996) AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. *J Biomol NMR* 8(4):477–486.
33. Wiederstein M, Sippl MJ (2007) ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. *Nucleic Acids Res* 35(Web Server issue):W407–W410.
34. Cojocaru V, Balali-Mood K, Sansom MS, Wade RC (2011) Structure and dynamics of the membrane-bound cytochrome P450 2C9. *PLOS Comput Biol* 7(8):e1002152.
35. Stansfeld PJ, Sansom MS (2011) From coarse grained to atomistic: A serial multiscale approach to membrane protein simulations. *J Chem Theory Comput* 7(4):1157–1166.
36. Pronk S, et al. (2013) GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. *Bioinformatics* 29(7):845–854.
37. Marrink SJ, Risselada HJ, Yefimov S, Tieleman DP, de Vries AH (2007) The MARTINI force field: Coarse grained model for biomolecular simulations. *J Phys Chem B* 111(27):7812–7824.
38. Cerame BI, et al. (1999) Prenatal diagnosis and treatment of 11 $\beta$ -hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia. *J Clin Endocrinol Metab* 84(9):3129–3134.